The discussion revolves around the complexities of Blinatumomab treatment for leukemia, with experts debating the reasons behind the partial clinical hold on cooperative group studies, concerns about combining treatments concurrently, and the potential impact of reducing chemotherapy intensity.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Topics also include the risk of CNS relapses, the significance of IT chemotherapy, and the emergence of CD19-negative relapses with Blinatumomab. The experts emphasize the need for longer-term follow-up and caution in modifying treatment regimens, highlighting the ongoing efforts to optimize leukemia therapies.